Biopsy means taking living tissue for a closer look
The Greek roots say life plus sight. Ernest Besnier coined biopsie in 1879, but Abulcasis was already needling thyroid goiters around the eleventh century. Today pathologists read stained slices—and so-called liquid biopsies read tumor DNA circulating in blood.
A biopsy extracts sample cells or tissue so clinicians can judge whether disease is present and how far it has spread. Surgeons, radiologists, dermatologists, gastroenterologists, dentists, and many other specialists perform them. Specimens may be fixed, dehydrated, embedded, sectioned, stained, and mounted for microscopy, or analyzed chemically. Removing an entire lump is an excisional biopsy; taking a wedge is incisional; core needles harvest tissue cylinders; finer needles aspirate cell clusters. When cancer is the question, pathologists also read surgical margins—clear or negative edges mean no disease at the cut border; positive margins may demand a wider excision.
History stretches further than the French coinage. The Arab physician Abulcasis (1013–1107) developed an early diagnostic biopsy by puncturing the thyroid and classifying goiters. Modern oncology still distinguishes a mere sample from a full resection—such as examining a mastectomy after an earlier needle diagnosis to grade the tumor and map its extent. Liquid biopsy is a related but different idea: blood or urine assays for circulating tumor cells or cell-free tumor DNA, not a cut of solid tissue. They offer less invasive monitoring, drug testing against circulating cells, mutation profiling, and treatment planning when repeat tissue sampling is risky or inadequate.
Cell-free DNA assays can access roughly a hundredfold more tumor DNA than assays limited to circulating tumor cells, analyzing fragments tumors shed into blood. A 2014 multi-institution study of 846 patients across 15 cancer types detected tumor DNA in more than 80 percent of those with metastatic disease and about 47 percent with localized tumors, without false positives in that report—though the test did not locate the tumor. Circulating-cell tests already exist commercially yet may lack insurance coverage. Whether needle, scalpel, or vial, the goal is the same: turn a fragment of the body into readable evidence.
Source: Biopsy
